GLP-1 weight loss drugs

New reports indicate that young people taking GLP-1 receptor agonists, the class of weight-loss and diabetes drugs that includes Ozempic and Wegovy, are showing nutritional deficiencies. The findings suggest the medications' appetite-suppressing effects may reduce overall nutrient intake in youth, raising questions about monitoring and supplementation as prescriptions for adolescents continue to rise.